CA3245205A1 - METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT - Google Patents
METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERTInfo
- Publication number
- CA3245205A1 CA3245205A1 CA3245205A CA3245205A CA3245205A1 CA 3245205 A1 CA3245205 A1 CA 3245205A1 CA 3245205 A CA3245205 A CA 3245205A CA 3245205 A CA3245205 A CA 3245205A CA 3245205 A1 CA3245205 A1 CA 3245205A1
- Authority
- CA
- Canada
- Prior art keywords
- insert
- day
- eye
- days
- vorolanib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263318822P | 2022-03-11 | 2022-03-11 | |
| US63/318,822 | 2022-03-11 | ||
| US202263390036P | 2022-07-18 | 2022-07-18 | |
| US63/390,036 | 2022-07-18 | ||
| PCT/US2023/064139 WO2023173088A1 (en) | 2022-03-11 | 2023-03-10 | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245205A1 true CA3245205A1 (en) | 2023-09-14 |
Family
ID=85873993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245205A Pending CA3245205A1 (en) | 2022-03-11 | 2023-03-10 | METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250205152A1 (https=) |
| EP (1) | EP4489749A1 (https=) |
| JP (1) | JP2025508127A (https=) |
| KR (1) | KR20250002220A (https=) |
| AU (1) | AU2023230975A1 (https=) |
| CA (1) | CA3245205A1 (https=) |
| IL (1) | IL315331A (https=) |
| TW (1) | TW202345803A (https=) |
| WO (1) | WO2023173088A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
| WO2018059556A1 (zh) | 2016-09-29 | 2018-04-05 | 贝达药业股份有限公司 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
| EP4537830A3 (en) * | 2017-06-13 | 2025-06-11 | EyePoint Pharmaceuticals, Inc. | Bioerodible drug delivery devices |
| AU2021340733A1 (en) * | 2020-09-14 | 2023-05-18 | EyePoint Pharmaceuticals, Inc. | Bioerodible ocular drug delivery insert and therapeutic method |
-
2023
- 2023-03-10 KR KR1020247033914A patent/KR20250002220A/ko active Pending
- 2023-03-10 CA CA3245205A patent/CA3245205A1/en active Pending
- 2023-03-10 JP JP2024553781A patent/JP2025508127A/ja active Pending
- 2023-03-10 AU AU2023230975A patent/AU2023230975A1/en active Pending
- 2023-03-10 IL IL315331A patent/IL315331A/en unknown
- 2023-03-10 US US18/843,566 patent/US20250205152A1/en active Pending
- 2023-03-10 TW TW112108996A patent/TW202345803A/zh unknown
- 2023-03-10 WO PCT/US2023/064139 patent/WO2023173088A1/en not_active Ceased
- 2023-03-10 EP EP23715381.2A patent/EP4489749A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250205152A1 (en) | 2025-06-26 |
| IL315331A (en) | 2024-10-01 |
| WO2023173088A1 (en) | 2023-09-14 |
| AU2023230975A1 (en) | 2024-09-19 |
| TW202345803A (zh) | 2023-12-01 |
| JP2025508127A (ja) | 2025-03-21 |
| EP4489749A1 (en) | 2025-01-15 |
| KR20250002220A (ko) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12551368B2 (en) | Bioerodible ocular drug delivery insert and therapeutic method | |
| US20250186398A1 (en) | Continuous dosing regimen for treatment of a condition of the eye | |
| US20230089914A1 (en) | Compositions comprising axitinib and methods of treating ocular disorders | |
| US20250205152A1 (en) | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert | |
| US20250186336A1 (en) | Method of treating wet age-related macular degeneration | |
| US20260083727A1 (en) | Pharmaceutical formulations of nintedanib for intraocular use | |
| CN118871106A (zh) | 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法 | |
| HK40118703A (zh) | 治疗湿性年龄相关性黄斑变性的方法 | |
| HK40118700A (zh) | 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法 | |
| TWI911436B (zh) | 生物可侵蝕之眼用藥物遞送插入物及治療方法 | |
| HK40118701A (zh) | 用於治疗眼睛病症的持续给药方案 | |
| CN118891040A (zh) | 治疗湿性年龄相关性黄斑变性的方法 | |
| CN118871107A (zh) | 用于治疗眼睛病症的持续给药方案 | |
| US20250025452A1 (en) | Compositions comprising axitinib and methods of treating ocular disorders | |
| HK40073855A (en) | Bioerodible ocular drug delivery insert and therapeutic method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240829 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240903 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240903 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240903 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250804 |